Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A Single-Center Experience.
- Author:
Kwang Duck RYU
1
;
Gwang Ha KIM
;
Seong Oh PARK
;
Kwang Jae LEE
;
Jung Youn MOON
;
Hye Kyung JEON
;
Dong Hoon BAEK
;
Bong Eun LEE
;
Geun Am SONG
Author Information
1. Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea. doc0224@pusan.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Lymphoma, B-cell, marginal zone;
Stomach;
Helicobacter pylori;
Eradication;
Radiotherapy
- MeSH:
Adult;
Aged;
Antineoplastic Agents/therapeutic use;
Female;
Gastric Mucosa;
Gastroscopy/*methods;
Helicobacter Infections/complications/*therapy;
*Helicobacter pylori;
Humans;
Lymphoma, B-Cell, Marginal Zone/complications/*therapy;
Male;
Middle Aged;
Retrospective Studies;
Stomach Neoplasms/complications/*therapy;
Treatment Outcome
- From:Gut and Liver
2014;8(4):408-414
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Helicobacter pylori eradication therapy has been used as a first-line treatment for H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, the management strategy for H. pylori-negative MALT lymphoma remains controversial. Therefore, the aim of this study was to examine the success rate of each treatment option for H. pylori-positive and H. pylori-negative gastric MALT lymphomas. METHODS: In total, 57 patients with gastric MALT lymphoma diagnosed between December 2000 and June 2012 were enrolled in the study. The treatment responses were compared between H. pylori-positive and H. pylori-negative gastric MALT lymphomas. RESULTS: Of the 57 patients, 43 (75%) had H. pylori infection. Forty-eight patients received H. pylori eradication as a first-line treatment, and complete remission was achieved in 31 of the 39 patients (80%) with H. pylori-positive MALT lymphoma and in five (56%) of the nine patients with H. pylori-negative MALT lymphoma; no significant difference was observed between the groups (p=0.135). The other treatment modalities, including radiation therapy, chemotherapy, and surgery, were effective irrespective of H. pylori infection status, with no significant difference in the treatment response between H. pylori-positive and H. pylori-negative MALT lymphomas. CONCLUSIONS: H. pylori eradication therapy may be considered as a first-line treatment regardless of H. pylori infection status.
